The EMA’s CHMP recommended approval of eight new medicines for September, including two new ovarian cancer therapies and a potential first oral treatment for hidradenitis suppurativa. The committee also backed multiple other medicines and label expansions during its monthly review cycle. While the CHMP issues opinions rather than final approvals, the recommendations typically signal which programs are likely to move through the next step toward EU marketing authorizations. For developers, the inclusion of ovarian cancer assets underscores continued regulatory focus on expanding options in hard-to-treat settings. The hidradenitis suppurativa item stands out as a route-of-administration shift, potentially changing the standard-of-care experience for patients who struggle with tolerability and adherence in existing regimens. Label expansions also indicate incremental evidence updates rather than only first-time approvals.